Key result
Combination therapy with a β-blocker and flecainide effectively controlled ventricular arrhythmias in pregnant patients with Andersen-Tawil syndrome when monotherapy failed.
Why the study?
Does beta-blocker plus flecainide combination therapy control arrhythmia in pregnant patients with Andersen-Tawil syndrome?
Does beta-blocker plus flecainide combination therapy control arrhythmia in pregnant patients with Andersen-Tawil syndrome?
Beta-blocker and flecainide combination therapy may be an effective and safe option for managing ventricular arrhythmias in pregnant patients with Andersen-Tawil syndrome when monotherapy fails.
Answers are grounded in this paper and cite their sources.
May support combination therapy for refractory arrhythmias in pregnant Andersen-Tawil syndrome; hypothesis-generating and requires prospective validation.
Andersen-Tawil syndrome (ATS) is a rare inherited ventricular arrhythmia (VA). Here, we reported two KCNJ2-associated ATS patients who got pregnant and underwent vaginal birth safely. Both individuals had VA, micrognathia without periodic paralysis. β-blocker plus flecainide could be an effective treatment combination when monotherapy failed to control arrhythmia.
No takes yet. Share an insight, caveat, or question.
Rujirachun et al. (2020) studied this question. Combination therapy with a β-blocker and flecainide effectively controlled ventricular arrhythmias in pregnant patients with Andersen-Tawil syndrome when monotherapy failed.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: